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Abstract
Background: U.S. hemodialysis patients with systemic lupus erythematosus (SLE) and end-stage renal disease
(ESRD) are less likely than other ESRD patients to have a permanent vascular access (fistula or graft) in place at the
dialysis start. We examined whether vascular access outcomes after dialysis start differed for SLE vs. other ESRD
patients.
Methods: Among U.S. patients initiating hemodialysis in 2010 with only a catheter (n = 40,911; 384 with SLE) and
using a permanent access on first dialysis (n = 13,073; 48 with SLE), we examined the association of SLE status with
time to first placement of a permanent access (among catheter-only patients) and to loss of access patency
(among patients using a permanent access on first dialysis), both censored 1 year after dialysis start, using
multivariable Cox proportional hazards models.
Results: Among catheter-only patients, 46.1 % vs. 54.5 % of those with SLE-ESRD vs. other ESRD had a permanent
access placed within 1 year after dialysis start. However, with adjustment, there was no association of 1-year
placement with SLE status [HR = 1.00 (95 % CI, 0.86-1.17)]. SLE-ESRD vs. other ESRD patients starting dialysis with a
permanent access were less likely to experience a 1-year loss of patency (43.8 % vs. 55.0 %), but this association was
not statistically significant after adjustment [HR = 0.88 (0.57-1.37)].
Conclusion: These results suggest that SLE-ESRD patients starting dialysis with a catheter are not more likely to
have a permanent access placed in the first year of dialysis, despite an observed lack of association of SLE status
with subsequent loss of vascular access patency among those starting dialysis with a permanent access.
Background
End-stage renal disease (ESRD) patients who undergo
hemodialysis with a permanent vascular access [arterio-
venous fistula (AVF) or grafts (AVG)] rather than a tem-
porary catheter generally have better outcomes [1–7]
and lower associated healthcare costs [8]. Thus, national
U.S. clinical guidelines promote the early placement of
AVFs and AVG (at least 6 months and 3–6 weeks prior
to anticipated dialysis start, respectively), such that a
mature, functioning vascular access is in place on first
dialysis [9]. Centers for Medicare & Medicaid Services
(CMS) tracks early placement through the ESRD Med-
ical Evidence form (CMS-2728), which collects data on
access type at first dialysis for all patients starting ESRD
treatment. CMS also promotes the placement of a per-
manent vascular access among hemodialysis patients
through regionally implemented quality incentive pro-
grams such as Fistula First, Catheter Last [10].
Previously, we found that systemic lupus erythemato-
sus (SLE) patients who developed ESRD were 40 % less
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likely to have a permanent vascular access in place at the
start of dialysis than other ESRD patients, despite being
more likely than other ESRD patients to have other indi-
cators of advanced ESRD care planning, such as receipt of
pre-ESRD nephrology care and earlier placement on the
deceased donor kidney transplant waitlist [11, 12]. Further,
O’Shaughnessy et al. [13] recently noted that ESRD pa-
tients with SLE were also less likely than ESRD patients
with other types of glomerulonephritis to have an AVF in
place at dialysis start. Here, using national claims data on
ESRD patients, we examined whether subsequent place-
ment of permanent vascular access differed for SLE-ESRD
patients compared to other ESRD patients who started
hemodialysis with only a catheter. Additionally, among
U.S. patients who used a permanent access on their first
hemodialysis treatment, we examined whether early loss
of patency, as evidenced by procedures aimed at maintain-
ing vascular access patency or placement of a new vas-
cular access, differed for SLE-ESRD vs. other ESRD
patients.
Methods
Study population and data sources
For this retrospective cohort study, data from the CMS-
2728 and Part A (inpatient) and Part B (outpatient) claims
were obtained from the United States Renal Data System
(USRDS) [14]. The study was approved by the Emory Insti-
tutional Review Board. Analyses were limited to patients
starting dialysis in 2010, the most recent year available such
that all patients had at least a year of potential follow-up. A
total of 117,836 incident adult and pediatric ESRD patients
were identified who initiated treatment from 1/1/10 to 12/
31/10. Patients were excluded if they had a missing attrib-
uted cause of ESRD [n = 2,190 (1.9 %)]; did not start on
hemodialysis [n = 19,646 (17.0 %); had fewer than 90 days
of hemodialysis [n = 4,683 (4.9 %)], did not have informa-
tion on starting vascular access [n = 810 (0.9 %)], or did not
have evidence of Part B claims [n = 23,381 (25.8 %)], leaving
67,478 patients (517 with SLE-ESRD and 66,961 with other
ESRD; Fig. 1). Patients without Part B claims were excluded
to avoid differential ascertainment of outpatient vascular
Fig. 1 Selection of study population among U.S. 2010 incident dialysis patients, overall and by systemic lupus erythematosus-attributed and other
end-stage renal disease. AVF, arteriovenous fistula; AVG, arteriovenous graft; ESRD, end-stage renal disease; SLE, systemic lupus erythematosus
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SLE-ESRD was defined as ESRD attributed to CMS-2728
ICD-9 code 710.0 (SLE). Other ESRD (the referent group)
included all other non-missing ICD-9 codes listed on the
CMS-2728.
Vascular access at dialysis start
Vascular access at dialysis start was determined from the
CMS-2728. Vascular access at dialysis start was catego-
rized as: having a catheter only [no permanent access
(AVF or AVG) in place], having a permanent access in
place but not used on first dialysis, and having a per-
manent access that was used on first dialysis.
Vascular access placement in first year of dialysis
Placement of a permanent access (AVF or AVG) was deter-
mined from Parts A and B claims data using Healthcare
Common Procedure Coding System (HCPCS) codes
(Additional file 1: Table S1). The date of placement
was defined as the first date after start of dialysis in which
an inpatient or outpatient code for placement was used.
Loss of vascular access patency in first year of dialysis
Loss of patency of a permanent access (AVF or AVG)
was similarly determined from Part A and B claims data
using HCPCS codes for revision procedures on the start-
ing access or placement of new accesses (AVF, AVG, or
catheter; Additional file 1: Table S1). The date of loss of
patency was defined as the first date after start of dialysis
on which an inpatient or outpatient code for a revision
or placement was used.
Other variables
Incident age, sex, and treatment modalities were obtained
from the USRDS standard analytic files. Race/ethnicity,
primary insurance at start of ESRD, smoking status, body
mass index (BMI), and presence of comorbid conditions
were all obtained from the CMS-2728. Race/ethnicity was
categorized as white, black, Hispanic, or other. Primary in-
surance at start of ESRD was categorized as private, Me-
dicaid, none, or other (including Medicare, which is rare
in SLE patients).
Statistical analysis
Patient characteristics were summarized overall and by at-
tributed cause and vascular access at dialysis start. For ana-
lysis of placement of permanent access within the first year
of dialysis, 40,911 patients with a catheter only at start of
dialysis (Fig. 1) were included; for analysis of loss of patency
of permanent access within the first year of dialysis, 13,073
patients with an AVF or AVG that was used on first dialysis
(Fig. 1) were included.. The outcomes were time from dialy-
sis start to first placement of AVF or AVG and time from
start to first revision of the starting access or placement of
a new access (Additional file 1: Table S1), with censoring
for transplant, switch to peritoneal dialysis, death, or end of
follow-up (1 year after dialysis start). Separate analyses for
AVF and AVG placement were censored for placement of
the other type of permanent access. Additional sensitivity
analyses (i) excluded children (age <18 years), to account
for greater likelihood of pediatric ESRD onset in SLE- vs.
non-SLE-ESRD; (ii) included only those with Medicare at
ESRD start, to account for differential capture of events in
the first 90 days of dialysis; (iii) included a comparison
group of other glomerulonephritis patients [13], to examine
whether SLE patients less likely than these potentially more
comparable patients to have a permanent access placed; (iv)
used 2:1 matching on age, sex, and race rather than statis-
tical adjustment; and (v) included all events prior to day 90
on day 91 and (vi) excluded all events prior to day 90 on
the estimates obtained in primary analyses, also to account
for potential differential capture of events prior to day 91,
when Medicare ESRD coverage for those patients <65 and
not disabled begins. This scenario may be more likely in
SLE, given patients’ younger age at ESRD start. For both
placement and loss of patency analyses, we generated
Kaplan-Meier curves by SLE-ESRD vs. other ESRD and es-
timated hazard ratios (HRs) and CIs using crude and multi-
variable Cox proportional hazards models, with adjustment
for age, sex, race/ethnicity, BMI, comorbid conditions, and
smoking and using complete case analysis. Outcomes were
not examined among the 13,494 remaining patients (Fig. 1)
who had an access in place that was not used on first dialy-
sis because the date of first use of the access cannot be de-
termined from claims data. Stata v. 14 (StataCorp, College
Station, TX) was used for all analyses and we adhered to
STROBE guidelines for reporting.
Results
Characteristics of the study population by SLE status and
vascular access at dialysis start
Patients with ESRD attributed to SLE were younger (mean
age, 40.3 vs. 64.3 years), more likely to be female (79.3 %
vs. 43.1 %) and black (54.9 % vs. 29.8 %), and more likely to
have Medicaid coverage at dialysis start (39.0 % vs. 26.9 %),
compared to patients with other attributed causes of ESRD
(P < 0.001 for all; Table 1). SLE-ESRD patients were less
likely than other ESRD patients to have comorbid condi-
tions and to smoke (Table 1). While low overall, transplant-
ation (2.5 % vs. 1.3 %, P = 0.01) and renal recovery (2.5 %
vs. 1.6 %; not statistically significant) within a year of dialy-
sis start were both more likely in SLE-ESRD than other
ESRD patients (Table 1).
Plantinga et al. BMC Nephrology  (2016) 17:64 Page 3 of 10
Table 1 Characteristics of 2010 incident U.S. hemodialysis patients, by vascular access at dialysis start and systemic lupus erythematosus status
Characteristic Overall Vascular Access on First Dialysis:
Any Catheter only AVF/AVG in place AVF/AVG used
Attributed Cause of ESRD:
SLE Other SLE Other SLE Other SLE Other
N (%) 67,748 (100 %) 517 (0.8 %) 66,961 (99.2 %) 384 (0.9 %) 40,527 (99.1 %) 85 (0.6 %) 13,409 (99.4 %) 48 (0.4 %) 13,025 (99.6 %)
Demographic
Mean (SD) age, years 64.1 (14.9) 40.3 (15.3)a 64.3 (14.8)a 39.0 (15.0)a 64.1 (15.3)a 41.7 (15.8)a 63.8 (14.3)a 48.6 (14.2)a 65.4 (13.6)a
Female, n (%) 29,276 (43.4 %) 410 (79.3 %)a 28,866 (43.1 %)a 315 (82.0 %)a 17,951 (44.3 %)a 64 (75.3 %)a 5,675 (42.3 %)a 31 (64.6 %)b 7,785 (59.8 %)b
Race/ethnicity, %
Non-Hispanic white 34,731 (51.5 %) 129 (25.0 %)a 34,602 (51.7 %)a 89 (23.2 %)a 20,813 (51.4 %) a 22 (25.9 %)a 6,644 (49.6 %)a 18 (37.5 %) 7,145 (54.9 %)
Black 20,221 (30.0 %) 284 (54.9 %)a 19,937 (29.8 %)a 221 (57.6 %)a 11,984 (29.6 %)a 42 (49.4 %)a 4,108 (30.6 %)a 21 (43.8 %) 3,845 (29.5 %)
Hispanic white 8,722 (12.9 %) 72 (13.9 %)a 8,650 (12.9 %)a 56 (14.6 %)a 5,526 (13.6 %)a 10 (11.8 %)a 1,829 (13.6 %)a —c 1,295 (9.9 %)
Other 3,804 (5.6 %) 32 (6.2 %)a 3,772 (5.6 %)a 18 (4.7 %)a 2,204 (5.4 %)a 11 (12.9 %)a 828 (6.2 %)a —c 740 (5.7 %)
Insurance at dialysis start, %
Private 16,546 (24.5 %) 137 (26.5 %)a 16,409 (24.5 %)a 93 (24.2 %)a 9,441 (23.3 %)a 25 (29.4 %)b 3,387 (25.3 %)b 19 (39.6 %) 3,264 (25.1 %)
Medicare/other 27,159 (40.3 %) 104 (20.1 %)a 27,055 (40.4 %)a 67 (17.5 %)a 16,037 (39.6 %)a 21 (24.7 %)b 5,315 (39.6 %)b 16 (33.3 %) 3,581 (27.5 %)
Medicaid 18,183 (27.0 %) 201 (38.9 %)a 17.982 (26.9 %)a 160 (41.7 %)a 10,897 (26.9 %)a 32 (37.7 %)b 3,821 (28.5 %)b —c 5,703 (43.8 %)
None 5,590 (8.3 %) 75 (14.5 %)a 5,515 (8.2 %)a 64 (16.7 %)a 4,152 (10.3 %)a —c 886 (6.6 %)b —c 477 (3.7 %)
Clinical
Pre-ESRD nephrology care, % 38,937 (65.7 %) 307 (67.0 %) 38,630 (65.7 %) 200 (60.2 %)b 18,042 (52.4 %)b 64 (81.0 %) 9,034 (74.4 %) 43 (91.5 %) 11,554 (94.3 %)
Mean (SD) BMI, kg/m2 29.5 (7.9) 27.3 (7.5)a 29.5 (7.9)a 27.2 (7.5)a 29.3 (8.0)a 27.7 (6.9)a 29.9 (7.9)a 27.3 (8.3)b 29.8 (7.7)b
Congestive heart failure, % 22,893 (33.9 %) 85 (16.4 %)a 22,808 (34.1 %)a 59 (15.4 %)a 14,292 (35.3 %)a 18 (21.2 %)b 4,819 (35.9 %)b —c 3,697 (28.4 %)
Diabetes, % 38,918 (57.7 %) 62 (12.0 %)a 38,856 (58.0 %)a 44 (11.5 %)a 22,940 (56.6 %)a 12 (14.1 %)a 8,401 (62.7 %)a —c 7,515 (57.7 %)a
Peripheral vascular disease, % 9,569 (14.2 %) 21 (4.1 %)a 9,548 (14.3 %)a 16 (4.2 %)a 5,494 (13.6 %)a —c 2,267 (16.9 %)b —c 1,787 (13.7 %)b
Smoking, % 4,369 (6.5 %) 26 (5.0 %) 4,343 (6.5 %) 13 (3.4 %)b 2,645 (6.5 %)b 10 (11.8 %) 889 (6.6 %) —c 810 (6.2 %)
Transplanted within 1 year, % 853 (1.3 %) 13 (2.5 %)b 840 (1.3 %)b —c 429 (1.1 %)b —c 160 (1.2 %) —c 252 (1.9 %)
Recovered renal function within 1 year, % 1048 (1.6 %) 13 (2.5 %) 1035 (1.6 %) 11 (2.9 %) 909 (2.2 %) —c 85 (0.6 %) —c 41 (0.3 %)
AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus
aP <0.001 and bP < 0.05 for SLE vs. other ESRD, by t or chi-square/Fisher’s exact test, as appropriate












Most SLE-ESRD patients (74.3 %) started dialysis with
only a catheter, while 9.3 % started dialysis using an AVF
or AVG; in contrast, 60.5 % and 19.5 % of other ESRD
patients started dialysis with a catheter only or using an
AVF/AVG, respectively (P < 0.001). Within subgroups
defined by starting vascular access, patterns by SLE sta-
tus of patient characteristics were generally similar to
the patterns in the overall dialysis patients (Table 1). For
those using an AVF/AVG on first dialysis, differences by
SLE status by female sex and black race were slightly at-
tenuated, relative to the overall population (Table 1).
SLE patients starting dialysis with an AVF/AVG were
older (mean age, 48.6 years) and more likely to have pri-
vate insurance than other SLE-ESRD patients (Table 1).
Association of SLE status with vascular access outcomes
Vascular access placement within 1 year
Among hemodialysis patients without a permanent ac-
cess at dialysis start, 46.1 % of SLE-ESRD patients and
54.5 % of other ESRD patients had a permanent access
placed within 1 year of dialysis start (Table 2). Crude
rates of AVF/AVG placement over the first year of dialy-
sis were 26 % lower among patients with SLE-ESRD who
did not have a permanent access in place at dialysis start,
relative to their counterparts with other ESRD (Fig. 2a;
Table 2). However, adjustment for demographics and
clinical characteristics rendered this association null
(Table 2), and this attenuation was largely driven by ad-
justment for differences in ages between SLE-ESRD and
other ESRD patients [age-adjusted HR: 0.96 (95 % CI,
0.83-1.12)]. Similar patterns were seen for AVF and AVG
placement individually, although crude results were not
statistically significant for AVG placement alone (Table 2).
Sensitivity analyses showed results similar to those obtained
in the primary analysis (Table 3).
Loss of vascular access patency in first year of dialysis
SLE-ESRD patients using a permanent access (AVF/
AVG) on first dialysis were less likely than their non-SLE
counterparts to experience a loss of patency of that ac-
cess within the first year (43.8 % vs. 55.0 %, P = 0.12;
Table 4). SLE-ESRD patients had 30 % lower crude rates of
access revision than other ESRD patients within the first
year of dialysis, but the association was not statistically sig-
nificant (Fig. 2b; Table 4). Adjustment for potential con-
founders attenuated the association. Results among those
starting with an AVF were similar to the overall results,
whereas results among those starting with an AVG showed
a greater magnitude of effect (46 % lower rates of access re-
visions among SLE-ESRD vs. other ESRD patients) but
without statistical significance, likely due to low numbers of
individuals and events in the SLE-ESRD subgroup (Table 4).
Results from sensitivity analyses excluding children were
similar to results from the primary analysis (Table 5).
Discussion
We found that, among U.S. hemodialysis patients start-
ing treatment in 2010 without a permanent access in
place, those with SLE-ESRD were equally as likely as
other ESRD patients to have an AVF or AVG placed in
the first year of dialysis after adjustment for potential
confounders, particularly age. These results, which were
robust to sensitivity analyses, suggest that the differential
prevalence of permanent access in place at the start of
Table 2 Association of placement of permanent vascular access with attribution of end-stage renal disease to systemic lupus
erythematosus vs. other causes, among U.S. incident hemodialysis patients who started dialysis in 2010 with only a catheter in place
Model No. (%) with permanent
access placed within 1 year
Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
All events
SLE-attributed ESRD 177 (46.1 %) 0.74 (0.64-0.86) 0.94 (0.81-1.09) 1.00 (0.86-1.17)
Other ESRD 22,076 (54.5 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.42 >0.9
All AVF placementsa
SLE-attributed ESRD 137 (35.7 %) 0.73 (0.62-0.87) 0.93 (0.79-1.11) 1.00 (0.84-1.18)
Other ESRD 17,300 (42.7 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.006 <0.001 0.43 >0.9
All AVG placementsa
SLE-attributed ESRD 40 (10.4 %) 0.77 (0.56-1.05) 1.00 (0.73-1.38) 1.06 (0.77-1.47)
Other ESRD 4,776 (11.8 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.41 0.10 >0.9 0.71
AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical:
body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
aTime-to-event analyses censored for placement of other type of access
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hemodialysis seen in prior studies of both adults (24 %
vs. 36 % for SLE vs. other ESRD patients) [11–13] and
children (23 % vs. 43 %) [15, 16] is not the result of SLE-
ESRD patients being more likely than other ESRD pa-
tients to have their permanent access placed after, rather
than before, hemodialysis start. Further, it suggests that
the substantial gap in permanent access placement by
SLE status at ESRD start does not narrow, even after a
year on treatment, which may subject SLE-ESRD pa-
tients receiving hemodialysis to greater risk of morbidity
and mortality [1–8] than their non-SLE counterparts.
One reason providers and patients might delay place-
ment of permanent access in a patient approaching
ESRD treatment that the patient is expected to receive a
kidney transplant shortly after hemodialysis treatment
begins. This scenario may be more common in SLE-
ESRD patients, who tend to be younger and, potentially,
better transplant candidates, as suggested by their relatively
greater rates of placement on the deceased donor waitlist
and transplantation [12, 17]. Here, we found that, while
early transplantation was nearly twice as common among
the SLE-ESRD vs. other ESRD patients with only a catheter
for access at the start of hemodialysis, the absolute likeli-
hood of transplantation within the first year of hemodialysis
among these SLE-ESRD patients was only 2.5 %, suggesting
that expected early transplantation is not a justification for
lack of permanent access placement at or before
hemodialysis start. Similarly, providers may be more likely
to anticipate renal recovery in SLE-ESRD [18] and avoid
vascular surgery referral, but we found that, while SLE pa-
tients who started dialysis with a catheter only were more
likely to recover renal function within a year than their
non-SLE counterparts, fewer than 3 % of these SLE patients
recovered renal function. Thus, anticipated recovery is also
not likely to play a large role in the continuing gap in per-
manent vascular access placement by SLE status among
hemodialysis patients after the first year of hemodialysis
treatment. The predominance of female sex among SLE-
ESRD patients might be another reason for the continued
disparity in vascular access placement by SLE status over
the first year of hemodialysis, due to potentially greater dif-
ficulty placing AVFs [19] and greater prevalence of body
image issues associated with permanent vascular access
[20] among females. However, adjustment for sex did not
change our results. Differential provider referrals for vascu-
lar access surgery by SLE status could be also affected by
greater likelihood of intravenous treatment history and/or
hypercoagulability in SLE patients, particularly those who
may have anti-phospholipid syndrome [21]; data were not
available to examine these potential factors.
We also found that, among hemodialysis patients who
started treatment with a permanent vascular access, loss of
patency of the vascular access was actually less common
among SLE-ESRD than other ESRD patients. However, this
association was not statistically significant, even before
adjustment. These results suggest that any provider
perceptions about increased risk of vascular access prob-
lems for SLE-ESRD patients vs. other ESRD patients on
hemodialysis due to clinical features of SLE [21], which
could lead to fewer referrals to vascular access surgery,
could be overestimated or even unfounded. However, these
results should be interpreted with caution due to the poten-
tial for confounding by indication. In other words, it is pos-
sible that SLE-ESRD patients who started hemodialysis with
a permanent vascular access were referred for vascular
access surgery because they were at lesser risk for loss of
vascular access patency than other SLE-ESRD patients, due
to clinical features of their SLE not captured in these ad-
ministrative data. Thus, we can only conclude that, among
those ESRD patients who are observed to have a permanent
access placed prior to the start of hemodialysis, SLE status
is likely not associated with greater risk of loss of patency.
Fig. 2 Time to access placement a and loss of access patency b in
the first year of dialysis, among U.S. incident hemodialysis patients
with systemic lupus erythematosus-attributed vs. other end-stage
renal disease in 2010. a, among patients who started with only a
catheter; b, among patients who used an arteriovenous fistula or
graft on first dialysis. ESRD, end-stage renal disease; SLE, systemic
lupus erythematosus
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We found that AVFs were placed more often than
AVGs in both SLE-ESRD and other ESRD patients in
the first year of dialysis, which is in line with national
clinical practice guidelines [9] and quality improvement
programs such as the Fistula First, Catheter Last initia-
tive [10]. However, the null association of permanent
vascular access placement with SLE status did not differ
by type of permanent access placed. We also found that
Table 3 Association of placement of permanent vascular access with attribution of end-stage renal disease to systemic lupus
erythematosus vs. other causes, among U.S. incident hemodialysis patients who started dialysis in 2010 with only a catheter in place:
sensitivity analyses
Model No. (%) with permanent
access placed within 1 year
Hazard ratio (95 % CI) for placement of permanent vascular access,
SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
Primary analysis
SLE-attributed ESRD 177 (46.1 %) 0.74 (0.64-0.86) 0.94 (0.81-1.09) 1.00 (0.86-1.17)
Other ESRD 22,076 (54.5 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.42 >0.9
Excluding patients <18 years olda
SLE-attributed ESRD 171 (46.2 %) 0.74 (0.64-0.86) 0.92 (0.79-1.08) 0.98 (0.84-1.15)
Other ESRD 22,053 (54.6 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.31 0.82
Only among patients with
Medicare at ESRD startb
SLE-attributed ESRD 67 (58.3 %) 0.77 (0.60-0.99) 0.83 (0.65-1.07) 0.83 (0.65-1.07)
Other ESRD 15,635 (64.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.20 0.04 0.15 0.15
SLE and other GN compared
to other ESRDc
SLE-attributed ESRD 177 (46.1 %) 0.73 (0.63-0.85) 0.93 (0.80-1.08) 0.97 (0.83-1.14)
Other GN-attributed ESRD 1,219 (48.6 %) 0.83 (0.78-0.88) 0.91 (0.86-0.96) 0.94 (0.89-1.00)
Other ESRD 20,857 (54.9 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P <0.001 <0.001/<0.001 0.35/<0.001 0.74/0.06
Matched analysisd
SLE-attributed ESRD 177 (46.1 %) 0.85 (0.71-1.02) 0.88 (0.73-1.06) 0.93 (0.77-1.13)
Other ESRD 350 (51.7 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.08 0.09 0.17 0.48
Events prior to 90 days included
on day 91
SLE-attributed ESRD 177 (46.1 %) 0.76 (0.65-0.88) 0.94 (0.81-1.10) 1.00 (0.86-1.17)
Other ESRD 22,076 (54.5 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.46 >0.9
Events prior to 90 days excludede
SLE-attributed ESRD 142 (40.7 %) 0.93 (0.79-1.10) 1.05 (0.89-1.25) 1.07 (0.91-1.27)
Other ESRD 13,653 (42.6 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.48 0.41 0.56 0.42
AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, GN glomerulonephritis, SLE systemic lupus eythematosus. Demographics: age
(continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
aExcluding n = 162 patients (14 SLE, 148 other) who were <18 years old
bExcluding n = 16,374 patients (269 SLE, 16,105 other) without Medicare at ESRD start
cOther GN included 2,511 patients with CMS-2728 ICD-9 codes for attributed cause of glomerulonephritis (582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82, 583.4,
580.0, and 582.0) or secondary glomerulonephritis/vasculitis (excluding SLE-ESRD; 287.0, 710.1, 283.11, 446.0, 446.4, 583.92, 446.20, 446.21, and 583.91)
dAmong n = 1061 patients, including 384 SLE patients and 677 matched non-SLE patients, using 2:1 matching on age group (<30, 30–49, and >50 years), sex (female
and male), and race (black and not black). Models stratified on matching variables to account for matching
eExcluding n = 8,491 patients (35 SLE, 8,456 other) with follow-up time <90 days
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loss of vascular access patency was more common among
patients starting hemodialysis with AVGs vs. AVFs, which
is consistent with prior evidence that access outcomes are
poorer in AVGs than AVFs [1, 22, 23]. Results were sug-
gestive that SLE-ESRD patients with AVGs were less likely
to experience loss of patency than other ESRD patients
with AVGs, whereas there was no association of SLE sta-
tus with revisions among patients with AVFs. However,
differences by SLE status were not statistically significant,
likely due to lack of power in subgroup analyses.
This study has several important strengths, including the
capture of all U.S. patients treated for ESRD, limited loss to
follow-up due to universal coverage of ESRD services by
CMS, completion of the CMS-2728 for all treated patients,
and availability of claims data for all inpatient and out-
patient services after start of dialysis. However, there are
limitations, in addition to those noted above, which deserve
mention. There is the potential for selection bias in the ex-
clusion of a large number of patients without Medicare Part
B coverage, and SLE-ESRD patients were more likely than
other ESRD patients (33.5 % vs. 25.4 %) to be excluded due
to lack of Part B coverage. This exclusion, while necessary
to include outpatient events, also limits generalizability to
the entire U.S. ESRD population. There is also the potential
for misclassification of the outcomes using claims data. We
cannot address the question of whether SLE-ESRD and
other ESRD patients who start hemodialysis with a perman-
ent access in place at dialysis start have the same rates of
access maturation and eventual use, because administrative
data do not capture which access was used during each dia-
lysis session. As with all observational studies, residual
confounding by unmeasured factors such as differences in
training and experience of regional vascular access surgeons
[24] is possible. There is also the possibility of over-
adjustment, given that some variables may be mediators as
well as confounders and that our power was limited due to
small sample sizes in some subgroups, such as SLE patients
with AVGs. However, we found that, after adjustment for
age, further adjustment did not change results substantially.
Sensitivity of the attribution of ESRD cause to SLE on the
CMS-2728 has been suggested to be low [25], although our
more recent study suggested much higher sensitivity (79 %)
for the capture of U.S. patients with a validated diagnosis of
SLE who have progressed to ESRD [26]; however, many
SLE patients may remain in the comparison group. Mis-
classification of access revision could have occurred by in-
cluding placement of a new access in the definition, since
accesses may be placed for other reasons, including
aneurysm formation and steal syndrome. Data are from
2010 and may not reflect current clinical practice regarding
vascular access placement and revisions generally, or specif-
ically in SLE patients. Finally, while we performed multiple
sensitivity analyses, we cannot fully address the possibility
of missed events in the first 90 days of dialysis, which may
differentially occur in SLE-ESRD patients.
Conclusion
We found that SLE-ESRD patients were not more likely
to have a permanent access placed in the first year of
dialysis, despite a substantial gap in access placement at
the start of hemodialysis [12] and despite an observed
lack of association of SLE status with subsequent loss of
Table 4 Association of loss of vascular access patencya with attribution of ESRD to SLE vs. other causes, among 2010 U.S. incident
hemodialysis patients who started dialysis with a permanent vascular access
Model No. (%) with access
revision within 1 year
Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
All patients
SLE-attributed ESRD 21 (43.8 %) 0.70 (0.45-1.09) 0.81 (0.52-1.26) 0.88 (0.57-1.37)
Other ESRD 7,169 (55.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.12 0.11 0.35 0.58
Among patients with AVFb
SLE-attributed ESRD 19 (44.2 %) 0.74 (0.46-1.17) 0.86 (0.54-1.37) 0.94 (0.59-1.50)
Other ESRD 5,735 (52.9 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.26 0.20 0.53 0.80
Among patients with AVGb
SLE-attributed ESRD —c 0.54 (0.13-2.15) 0.57 (0.14-2.30) 0.61 (0.15-2.47)
Other ESRD 1,434 (65.8 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.35 0.38 0.43 0.49
AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical:
body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
aDefined as a revision or placement of a new AVF, AVG, or catheter (see Table 1)
bN = 10,890 and 2,183 for AVF and AVG, respectively
cNot reportable due to cell size < 10
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access patency. SLE-ESRD patients are seen by multiple
providers, potentially increasing opportunities for shared
decision-making and coordinated care; yet, this popula-
tion does not have adequate hemodialysis vascular
access. Future studies should focus on provider and
patient perceptions of permanent vascular access for
hemodialysis in SLE-ESRD and, more generally, on the
roles of nephrologists, rheumatologists, and patients in
ensuring high-quality care and optimal outcomes in
hemodialysis.
Table 5 Association of loss of vascular access patencya with attribution of ESRD to SLE vs. other causes, among 2010 U.S. incident
hemodialysis patients who started dialysis with a permanent vascular access: sensitivity analyses
Model No. (%) with access
revision within 1 year
Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
Primary analysis
SLE-attributed ESRD 21 (43.8 %) 0.70 (0.45-1.09) 0.81 (0.52-1.26) 0.88 (0.57-1.37)
Other ESRD 7,169 (55.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.12 0.11 0.35 0.58
Excluding patients <18 years oldb
SLE-attributed ESRD 21 (43.8 %) 0.70 (0.45-1.08) 0.81 (0.52-1.26) 0.88 (0.57-1.37)
Other ESRD 7,165 (55.1 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.12 0.11 0.35 0.57
Only among patients with
Medicare at ESRD startc
SLE-attributed ESRD —d 0.91 (0.55-1.52) 0.86 (0.52-1.42) 0.92 (0.55-1.53)
Other ESRD 1125 (13.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.76 0.73 0.55 0.75
SLE and other GN compared
to other ESRDe
SLE-attributed ESRD —d 0.69 (0.44-1.07) 0.80 (0.52-1.24) 0.87 (0.56-1.35)
Other GN-attributed ESRD 60 (6.9 %) 0.79 (0.71-0.88) 0.87 (0.78-0.96) 0.91 (0.82-1.02)
Other ESRD 1433 (11.8 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P <0.001 0.10/<0.001 0.32/0.008 0.54/0.09
Matched analysisf
SLE-attributed ESRD 21 (43.8 %) 0.71 (0.42-1.19) 0.70 (0.42-1.15) 0.81 (0.47-1.40)
Other ESRD 89 (58.2 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.08 0.19 0.16 0.46
Events prior to 90 days included
on day 91
SLE-attributed ESRD 21 (43.8 %) 0.73 (0.47-1.13) 0.81 (0.52-1.27) 0.88 (0.57-1.37)
Other ESRD 7,169 (55.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.12 0.16 0.36 0.57
Events prior to 90 days excludedg
SLE-attributed ESRD 13 (32.5 %) 0.85 (0.49-1.46) 0.76 (0.44-1.31) 0.84 (0.48-1.45)
Other ESRD 3,377 (36.6 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.59 0.56 0.32 0.52
AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, GN glomerulonephritis, SLE systemic lupus eythematosus. Demographics: age
(continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
aDefined as a revision or placement of a new AVF, AVG, or catheter (see Table 1)
bExcluding n = 14 patients (4 SLE, 10 other) who were <18 years old
cExcluding n = 4,375 patients (23 SLE, 4,352 other) without Medicare at ESRD start
dNot reportable due to cell size < 10
eOther GN included 864 patients with CMS-2728 ICD-9 codes for attributed cause of glomerulonephritis (582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82, 583.4,
580.0, and 582.0) or secondary glomerulonephritis/vasculitis (excluding SLE-ESRD; 287.0, 710.1, 283.11, 446.0, 446.4, 583.92, 446.20, 446.21, and 583.91)
fAmong n = 201 patients, including 48 SLE patients and 153 matched non-SLE patients, using 2:1 matching on age group (<30, 30–49, and >50 years), sex (female
and male), and race (black and not black). Models stratified on matching variable to account for matching
gExcluding n = 3,801 patients (35 SLE, 8,456 other) with follow-up time <90 days
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